By switaschek, 20 July, 2020 After total T level at target, monitor q6-12mo;1 annually, per ACP & ES2,3
By switaschek, 20 July, 2020 Adjust dosing to target middle of NL ref range2 (middle tertile of NL, per AUA1)
By switaschek, 20 July, 2020 Recheck total T after initiation; timing depends on prep used, per AUA;1 ES recommends recheck after 3-6mo for most preps (can check after 1wk on gels)2
By switaschek, 20 July, 2020 Monitor total T levels target middle of NL ref range re eval sx once at target1 3 d c testosterone replacement tx TRT if sx not improved1 2
By vgreene, 20 July, 2020 Severity of illness may vary from person to person; among persons w/ extensive/close contact w/ vulnerable populations (eg, HCWs), even mild signs/sx (eg, sore throat) of possible SARS-CoV-2 infxn should prompt consideration for testing. Additional info a
By vgreene, 20 July, 2020 Sx and presentations may be different in children; consider referencing guidance for neonates and for Multisystem Inflammatory Syndrome in Children (MIS-C)
By vgreene, 20 July, 2020 Consider testing for other causes of resp illness (eg, influenza) in addition to testing for SARS-CoV-2 depending on pt age, season, clinical setting; detection of 1 resp pathogen (eg, influenza) does not exclude potential for co-infxn
By vgreene, 20 July, 2020 Most pts w/ confirmed COVID-19 have developed fever and/or sx of acute resp illness (eg, cough) but some infected pts may present w/ other sx (eg, altered smell/taste)
By vgreene, 20 July, 2020 Use judgment to determine if pt has signs or symptoms compatible w/ COVID-19 and whether pt should be tested
By vgreene, 20 July, 2020 Use authorized nucleic acid or antigen detection assays that have received an FDA EUA. Follow authorized labeling; be familiar w/ the tests’ performance characteristics/limitations